An update on brivaracetam for the treatment of pediatric partial epilepsy

References

• Klein P, Diaz A, Gasalla T, et al. A review of the pharmacology and clinical efficacy of brivaracetam. Clin Pharmacol. 2018;10:1–22.
   PubMed Web of Science ®Google Scholar
• Qiu S, Tehrani KA, Sergeyev S, et al. Stereochemistry of the Brivaracetam Diastereoisomers. Chirality. 2016;28:215–225.
   PubMed Web of Science ®Google Scholar
• Bialer M. New antiepileptic drugs that are second generation to existing antiepileptic drugs. Expert Opin Investig Drugs. 2006;15:637–647.
   PubMed Web of Science ®Google Scholar
• Makke Y, Abou-Khalil B. Brivaracetam efficacy and safety in focal epilepsy. Expert Rev Neurother. 2019;19:955–964.
   PubMed Web of Science ®Google Scholar
• Russo E, Citraro R, Mula M. The preclinical discovery and development of brivaracetam for the treatment of focal epilepsy. Expert Opin Drug Discov. 2018;9(11):1169–1178.
   Google Scholar
• Steinhoff BJ, Staack AM. Levetiracetam and brivaracetam: a review of evidence from clinical trials and clinical experience. Ther Adv Neurol Disord. 2019;12:1756286419873518.
   Web of Science ®Google Scholar
• Sills GJ, Rogawski MA. Mechanisms of action of currently used antiseizure drugs. Neuropharmacology. 2020;168:107966.
   PubMed Web of Science ®Google Scholar
• Kappes JA, Hayes WJ, Strain JD, et al. Brivaracetam: an adjunctivetreatment for partial-onset seizures. J Clin Pharmacol. 2017;57:811–817.
   PubMed Web of Science ®Google Scholar
• Coppola G, Iapadre G, Operto FF, et al. New developments in the management of partial-onset epilepsy: role of brivaracetam. Drug Des Devel Ther. 2017;11:643–657.
   PubMed Web of Science ®Google Scholar
• Daniels V, Wood M, Leclercq K, et al. Modulation of the conformational state of the SV2A protein by an allosteric mechanism as evidenced by ligand binding assays. Br J Pharmacol. 2013;169:1091–1101.
   PubMed Web of Science ®Google Scholar
• Verrotti A, Grasso EA, Cacciatore M, et al. Potential role of brivaracetam in pediatric epilepsy. Acta Neurol Scand. 2021;143:19–26.
   PubMed Web of Science ®Google Scholar
• Gillard M, Fuks B, Leclercq K, et al. Binding characteristics of brivaracetam, a selective, high affinity SV2A ligand in rat, mouse and human brain: relationship to anti-convulsant properties. Eur J Pharmacol. 2011;664:36–44.
   PubMed Web of Science ®Google Scholar
• Matagne A, Margineanu DG, Kenda B, et al. Anti-convulsive and anti-epileptic properties of brivaracetam (ucb 34714), a high-affinity ligand for the synaptic vesicle protein, SV2A. Br J Pharmacol. 2008;154:1662–1671.
   PubMed Web of Science ®Google Scholar
• Feng G, Xiao F, Lu Y, et al. Down-regulation synaptic vesicle protein 2A in the anterior temporal neocortex of patients with intractable epilepsy. J Mol Neurosci. 2009;39:354–359.
   PubMed Web of Science ®Google Scholar
• Klitgaard H, Matagne A, Nicolas JM, et al. Brivaracetam: rationale for discovery and preclinical profile of a selective SV2A ligand for epilepsy treatment. Epilepsia. 2016;57:538–548.
   PubMed Web of Science ®Google Scholar
• Rolan P, Sargentini-Maier ML, Pigeolet E, et al. The pharmacokinetics, CNS pharmacodynamics and adverse event profile of brivaracetam after multiple increasing oral doses in healthy men. Br J Clin Pharmacol. 2008;66:71–75.
   PubMed Web of Science ®Google Scholar
• Kalss G, Rohracher A, Leitinger M, et al. Intravenous brivaracetam in status epilepticus: a retrospective single-center study. Epilepsia. 2018;59(Suppl 2):228–233.
   PubMed Web of Science ®Google Scholar
• Brigo F, Lattanzi S, Nardone R, et al. Intravenous Brivaracetam in the treatment of status epilepticus: a systematic review. CNS Drugs. 2019;33:771–781.
   PubMed Web of Science ®Google Scholar
• Santamarina E, ParejoCarbonell B, Sala J, et al. Use of intravenous brivaracetam in status epilepticus: a multicenter registry. Epilepsia. 2019;60:1593–1601.
   PubMed Web of Science ®Google Scholar
• Sargentini-Maier ML, Espié P, Coquette A, et al. Pharmacokinetics and metabolism of 14C-brivaracetam, a novel SV2A ligand, in healthy subjects. Drug Metab Dispos. 2008;36:36–45.
   PubMed Web of Science ®Google Scholar
• Tian X, Yuan M, Zhou Q, et al. The efficacy and safety of brivaracetam at different doses for partial-onset epilepsy: a meta-analysis of placebo-controlled studies. Expert Opin Pharmacother. 2015;16:1755–1767.
   PubMed Web of Science ®Google Scholar
• Klein P, Tyrlikova I, Brazdil M, et al. Brivaracetam for the treatment of epilepsy. Expert Opin Pharmacother. 2016;17:283–295.
   PubMed Web of Science ®Google Scholar
• Milovanović JR, Janković SM, Pejčić A, et al. Evaluation of brivaracetam: a new drug to treat epilepsy. Expert Opin Pharmacother. 2017;18:1381–1389.
   PubMed Web of Science ®Google Scholar
• Willems LM, Bauer S, Rosenow F, et al. Recent advances in the pharmacotherapy of epilepsy: brivaracetam and perampanel as broad-spectrum antiseizure drugs for the treatment of epilepsies and status epilepticus. Expert Opin Pharmacother. 2019;20:1755–1765.
   PubMed Web of Science ®Google Scholar
• Bd M, Chanteux H, Jm N, et al. A review of the drug-drug interactions of the antiepileptic drug brivaracetam. Epilepsy Res. 2020;163:106327.
   PubMed Web of Science ®Google Scholar
• Steinhoff BJ, Bacher M, Blickhan M, et al. Is brivaracetam-induced elevation of carbamazepine-epoxide levels common and clinically relevant? - A case series. Epilepsy Res. 2020;159:106236.
   PubMed Web of Science ®Google Scholar
• Moseley BD, Otoul C, Staelens L, et al. Pharmacokinetic interaction of brivaracetam on other antiepileptic drugs in adults with focal seizures: pooled analysis of data from randomized clinical trials. Epilepsy Res. 2019;158:106218.
   PubMed Web of Science ®Google Scholar
• Stockis A, Chanteux H, Rosa M, et al. Brivaracetam and carbamazepine interaction in healthy subjects and in vitro. Epilepsy Res. 2015;113:19–27.
   PubMed Web of Science ®Google Scholar
• Brodie MJ, Fakhoury T, McDonough B, et al. Brivaracetam-induced elevation of carbamazepine epoxide levels: a post-hoc analysis from the clinical development program. Epilepsy Res. 2018;145:55–62.
   PubMed Web of Science ®Google Scholar
• Schoemaker R, Wade JR, Stockis A. Brivaracetam population pharmacokinetics and exposure-response modeling in adult subjects with partial-onset seizures. J Clin Pharmacol. 2016;56:1591–1602.
   PubMed Web of Science ®Google Scholar
• Schoemaker R, Jr W, Stockis A. Brivaracetam population pharmacokinetics in children with epilepsy aged 1 month to 16 years. Eur J Clin Pharmacol. 2017;73:727–733.
   PubMed Web of Science ®Google Scholar
• Stockis A, Watanabe S, Scheen AJ, et al. Effect of rifampin on the disposition of brivaracetam in human subjects: further insights into brivaracetam hydrolysis. Drug Metab Dispos. 2016;44:792–799.
   PubMed Web of Science ®Google Scholar
• Brodie MJ, Ben-Menachem E. Cannabinoids for epilepsy: what do we know and where do we go? Epilepsia. 2018;59:291–296.
   PubMed Web of Science ®Google Scholar
• Klotz KA, Hirsch M, Heers M, et al. Effects of cannabidiol on brivaracetam plasma levels. Epilepsia. 2019;60:e74–e77.
   PubMed Web of Science ®Google Scholar
• European Medicines Agency. Summary of opinion (initial authorisation) for Briviact (brivaracetam) [EMA/CHMP/742520/2015]. London: UK European Medicines Agency; 2015.
   Google Scholar
• Schubert-Bast S, Willems LM, Kurlemann G, et al. Postmarketing experience withbrivaracetam in the treatment of focal epilepsy in children and adolescents. Epilepsy Behav. 2018;89:89‐93.
   PubMed Web of Science ®Google Scholar
• Van PW, Hirsch E, Johnson M, et al. Efficacy and tolerability of adjunctive brivaracetam in adults with uncontrolled partial-onset seizures: a phase IIb, randomized, controlled trial. Epilepsia. 2013;54:89–97.
   Web of Science ®Google Scholar
• Biton V, Sf B, Abou-Khalil B, et al. Brivaracetam as adjunctive treatment for uncontrolled partial epilepsy in adults: a phase III randomized, double-blind, placebo-controlled trial. Epilepsia. 2014;55:57–66.
   PubMed Web of Science ®Google Scholar
• Klein P, Schiemann J, Sperling MR, et al. A randomized, double-blind, placebo-controlled, multicenter, parallel-group study to evaluate the efficacy and safety of adjunctive brivaracetam in adult patients with uncontrolled partial-onset seizures. Epilepsia. 2015;56:1890–1898.
   PubMed Web of Science ®Google Scholar
• Kwan P, Trinka E, Van PW, et al. Adjunctive brivaracetam for uncontrolled focal and generalized epilepsies: results of a phase III, double-blind, randomized, placebo-controlled, flexible-dose trial. Epilepsia. 2014;55:38–46.
   PubMed Web of Science ®Google Scholar
• Liu E, Dilley D, McDonough B, et al. Safety and tolerability of adjunctive Brivaracetam in pediatric patients < 16 years with epilepsy: an open-label trial. Paediatr Drugs. 2019;21:291–301.
   PubMed Web of Science ®Google Scholar
• Nissenkorn A, Tzadok M, Bar-Yosef O, et al. Treatment with brivaracetam in children - The experience of a pediatric epilepsy center. Epilepsy Behav. 2019;101:106541.
   PubMed Web of Science ®Google Scholar
• McGuire S, Silva G, Lal D, et al. Safety and efficacy of Brivaracetam in pediatric refractoryepilepsy: a single-center clinical experience. J Child Neurol. 2020;35:102‐105.
   PubMed Web of Science ®Google Scholar
• Visa-Reñé N, Raspall-Chaure M, Paredes-Carmona F, et al. Clinical experience with brivaracetam in a series of 46 children. Epilepsy Behav. 2020;107:107067.
   PubMed Web of Science ®Google Scholar
• Steinig I, Von Podewils F, Moddel G, et al. Postmarketing experience with brivaracetam in the treatment of epilepsies: a multicenter cohort study from Germany. Epilepsia. 2017;58:1208–1216.
   PubMed Web of Science ®Google Scholar
• Strzelczyk A, Kay L, Bauer S, et al. Use of brivaracetam in genetic generalized epilepsies and for acute, intravenous treatment of absence status epilepticus. Epilepsia. 2018;59:1549–1556.
   PubMed Web of Science ®Google Scholar
• Willems LM, Bertsche A, Bösebeck F, et al. A. efficacy, retention, and tolerability of Brivaracetam in patients with epileptic encephalopathies: a multicenter cohort study from Germany. Front Neurol. 2018;9:569.
   PubMed Web of Science ®Google Scholar
• Patel AD, Badalamenti V, Gasalla T, et al. Safety and tolerability of adjunctive brivaracetam in children with focal seizures: interim analysis of pooled data from two open-label trials. Eur J Paediatr Neurol. 2020;25:68–76.
   PubMed Web of Science ®Google Scholar
• Van Paesschen W, Hirsch E, Johnson M, et al. Efficacy and tolerability of adjunctive brivaracetam in adults with uncontrolled partial-onset seizures: a phase IIb, randomized, controlled trial. Epilepsia. 2013;54:89–97.
   PubMed Web of Science ®Google Scholar
• Klein P, Schiemann J, Sperling MR, et al. A randomized, double-blind, placebo-controlled, multicenter, parallel-group study to evaluate the efficacy and safety of adjunctive brivaracetam in adult patients with uncontrolled partial-onset seizures. Epilepsia. 2015;56:1890–1898.
   PubMed Web of Science ®Google Scholar
• Brandt C, Klein P, Badalamenti V, et al. Safety and tolerability of adjunctive brivaracetam in epilepsy: in-depth pooled analysis. Epilepsy Behav. 2020;103:106864.
   PubMed Web of Science ®Google Scholar
• Villanueva V, López-González FJ, Mauri JA, et al. BRIVA-LIFE-A multicenter retrospective study of the long-term use of brivaracetam in clinical practice. Acta Neurol Scand. 2019;139:360–368.
   PubMed Web of Science ®Google Scholar
• Toledo M, Whitesides J, Schiemann J, et al. Safety, tolerability, and seizure control during long-term treatment with adjunctive brivaracetam for partial-onset seizures. Epilepsia. 2016;57:1139–1151.
   PubMed Web of Science ®Google Scholar
• O’Brien TJ, Borghs S, He QJ, et al. Long-term safety, efficacy, and quality of life outcomes with adjunctive brivaracetam treatment at individualized doses in patients with epilepsy: an up to 11-year, open-label, follow-up trial. Epilepsia. 2020;61:636–646.
   PubMed Web of Science ®Google Scholar
• Meador KJ, Laloyaux C, Elmoufti S, et al. Time course of drug-related treatment-emergent adverse side effects of brivaracetam. Epilepsy Behav. 2020;111:107212.
   PubMed Web of Science ®Google Scholar
• Theochari E, Cock H, Lozsadi D, et al. Brivaracetam in adults with drug-resistant epilepsy and psychiatric comorbidities. Epilepsy Behav. 2019;90:129–131.
   PubMed Web of Science ®Google Scholar
• Toledo M, Abraira L, Mazuela G, et al. Effect of brivaracetam on the anger levels of epilepsy patients. A prospective open-labelled controlled study. Seizure. 2019;69:198–203.
   PubMed Web of Science ®Google Scholar
• Yates SL, Fakhoury T, Liang W, et al. An open-label, prospective, exploratory study of patients with epilepsy switching from levetiracetam to brivaracetam. Epilepsy Behav. 2015;52:165–168.
   PubMed Web of Science ®Google Scholar
• Sanon NT, Gagné J, Wolf DC, et al. Favorable adverse effect profile of brivaracetam vs levetiracetam in a preclinical model. Epilepsy Behav. 2018;79:117–125.
   PubMed Web of Science ®Google Scholar
• Brivaracetam (Brivlera) [Internet]. Ottawa (ON): Canadian Agency for Drugs and Technologies in Health. [2017 Feb]. Available from: https://www.ncbi.nlm.nih.gov/books/NBK447909
   Google Scholar
• Hellerslia V, Asistido JM, Iyamu A. Brivaracetam for epilepsy. JAAPA. 2019;32:21–22.
   PubMedGoogle Scholar
• Tiet MY, George J. Brivaracetam and levetiracetam dose adjustments leading to behavioural adverse effects. Postgrad Med J. 2017;93:566.
   PubMed Web of Science ®Google Scholar
• Feyissa AM. Brivaracetam in the treatment of epilepsy: a review of clinical trial data. Neuropsychiatr Dis Treat. 2019;15:2587–2600.
   PubMed Web of Science ®Google Scholar
• Iapadre G, Balagura G, Zagaroli L, et al. Pharmacokinetics and drug interaction of antiepileptic drugs in children and adolescents. PaediatrDrugs. 2018;20:429–453.
   Google Scholar
• Verrotti A, Iapadre G, Di Donato G, et al. Pharmacokinetic considerations for anti-epileptic drugs in children. Expert Opin Drug Metab Toxicol. 2019;15:199–211.
   PubMed Web of Science ®Google Scholar
• Schoemaker R, Jr W, Stockis A. Extrapolation of a Brivaracetam exposure-response model from adults to children with focal seizures. Clin Pharmacokinet. 2018;57:843–854.
   PubMed Web of Science ®Google Scholar
• Verrotti A, Tambucci R, Di Francesco L, et al. The role of polytherapy in the management of epilepsy: suggestions for rational antiepileptic drug selection. Expert Rev Neurother. 2020;20:167–173.
   PubMed Web of Science ®Google Scholar